03 April 2015
: Case report
Small-Fiber Neuropathy in Pompe Disease: First Reported Cases and Prospective Screening of a Clinic Cohort
Unusual clinical course, Educational Purpose (only if useful for a systematic review or synthesis)
Lisa D. Hobson-WebbABCDEF, Stephanie L. AustinABDE, Sneha JainBE, Laura E. CaseABDE, Karla GreeneBE, Priya S. KishnaniABCDEFGDOI: 10.12659/AJCR.893309
Am J Case Rep 2015; 16:196-201
Abstract
BACKGROUND: Prior autopsy reports demonstrate glycogen deposition in Schwann cells of the peripheral nerves in patients with infantile and late-onset Pompe disease (LOPD), but little is known about associated clinical features.
CASE REPORT: Here, we report the first confirmed cases of small-fiber neuropathy (SFN) in LOPD and present the results of a first attempt at screening for SFN in this patient population. After confirming small-fiber neuropathy in 2 LOPD patients, 44 consecutive Pompe patients (iOPD=7, LOPD n=37) presenting to the Duke University Glycogen Storage Disease Program between September 2013 and November 2014 were asked to complete the 21-item Small-Fiber Neuropathy Screening List (SFNSL), where a score of ≥11 is considered to be a positive screen. Fifty percent of patients had a positive SFN screen (mean score 11.6, 95% CI 9.0–14.2). A modest correlation between the SFNSL score and current age was seen (r=0.38, p=0.01), along with a correlation with duration of ERT (r=0.31, p=0.0495). Trends toward correlation with forced vital capacity and age at diagnosis were also present. Women had a higher mean SFNSL score (14.2) than men (8.2, p=0.017).
CONCLUSIONS: SFN may occur in association with Pompe disease and precede the diagnosis. Further studies are needed to determine its true prevalence and impact.
Keywords: Child, Cohort Studies, Erythromelalgia - etiology, Glycogen Storage Disease Type II - complications, Questionnaires, Risk Factors, Sex Factors, Vital Capacity
SARS-CoV-2/COVID-19
11 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936496
09 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937505
29 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937105
08 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937212
In Press
12 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936915
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937139
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936496
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935207
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399